Here are four key notes:
1. Epigenomics developed the test, and it is available in the U.S. through a joint commercialization agreement with Polymedco.
2. The Epi proColon test detects Epigenomics proprietary Septin9 DNA methylation biomarker for colorectal cancer in cell-free DNA circulating in blood.
3. The test was approved by the FDA in April.
4. Epi proColon provides an alternative to stool testing or colonoscopy.
More articles on GI/endoscopy:
FMT helps reduce recurring episodes of C. Diff in children: 4 findings
GIQuIC registry hits 3M colonoscopy cases: 5 things to know
Certain body sugars help prevent UC & colon cancer — 5 points
